Oseni is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. It is a combination of two prescription medications, alogliptin and pioglitazone. Alogliptin belongs to a group of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by stopping the DPP-4 enzyme from removing a hormone that is responsible for telling your body to release insulin after you eat. This allows insulin to be released, which lowers blood sugar. Pioglitazone belongs to a group of drugs called thiazolidinediones. It lowers blood sugar by helping your body use its natural insulin better.
Oseni comes in tablet form and is usually taken once daily, with or without food. Do not break or cut Oseni tablets before swallowing.
Some of the common side effects of Oseni include stuffy or runny nose and sore throat, back pain, and cold-like symptoms.
WARNING: CONGESTIVE HEART FAILURE
- Thiazolidinediones, including pioglitazone, which is a component of Oseni, cause or exacerbate congestive heart failure in some patients.
- After initiation of Oseni, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone in Oseni must be considered.
- Oseni is not recommended in patients with symptomatic heart failure.
- Initiation of Oseni in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated.